Usefulness of Pharmacogenetic Analysis in Psychiatric Clinical Practice: A Case Report

키워드

참고문헌 (47)

1. Kodesh A, "Epidemiology and comorbidity of severe mental illnesses in the community: findings from a computerized mental health registry in a large Israeli health organization", Soc Psychiatry Psychiatr Epidemiol, 47, pp.1775~1782 (2012)[DOI]
2. Angst J, "The epidemiology of common mental disorders from age 20 to 50: results from the prospective Zurich cohort study", Epidemiol Psychiatr Sci, 25, pp.24~32 (2016)[DOI]
3. Nuss P, "Treatment practices in the management of patients with bipolar disorder in France. The TEMPPO study", Encephale, 38, pp.75~85 (2012)[DOI]
4. Costa e Silva JA, "Personalized medicine in psychiatry: new technologies and approaches", Metabolism, 62(Suppl 1), pp.S40~S44 (2013)[DOI]
5. Samer CF, "Applications of CYP450 testing in the clinical setting", Mol Diagn Ther, 17, pp.165~184 (2013)[DOI]
6. Nivoli AM, "Treatment strategies according to clinical features in a naturalistic cohort study of bipolar patients: a principal component analysis of lifetime pharmacological and biophysic treatment options", Eur Neuropsychopharmacol, 23, pp.263~275 (2013)[DOI]
7. Bernardo M, "Recommendations for switching antipsychotics. A position statement of the Spanish Society of Psychiatry and the Spanish Society of Biological Psychiatry", Rev Psiquiatr Salud Ment, 4, pp.150~168 (2011)[DOI]
8. "Table of pharmacogenomic biomarkers in drug labeling" (2015)[URL]
9. Winner J, "Psychiatric pharmacogenomics predicts health resource utilization of outpatients with anxiety and depression", Transl Psychiatry, 3, pp.e242~ (2013)[DOI]
10. Stingl JC, "Genetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function", Mol Psychiatry, 18, pp.273~287 (2013)[DOI]
11. Hiemke C, "Interactions and monitoring of antipsychotic drugs", Handb Exp Pharmacol, (212), pp.241~265 (2012)
12. Ravyn D, "CYP450 pharmacogenetic treatment strategies for antipsychotics: a review of the evidence", Schizophr Res, 149, pp.1~14 (2013)[DOI]
13. Cacabelos R, "Genomics and pharmacogenomics of schizophrenia", CNS Neurosci Ther, 17, pp.541~565 (2011)[DOI]
14. Nakamura A, "Lack of correlation between the steady-state plasma concentrations of aripiprazole and haloperidol in Japanese patients with schizophrenia", Ther Drug Monit, 36, pp.815~818 (2014)[DOI]
15. Eiermann B, "The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine", Br J Clin Pharmacol, 44, pp.439~446 (1997)
16. Trenton A, "Fatalities associated with therapeutic use and overdose of atypical antipsychotics", CNS Drugs, 17, pp.307~324 (2003)[DOI]
17. Zhang JP, "Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction", Expert Opin Drug Metab Toxicol, 7, pp.9~37 (2011)[DOI]
18. Ingelman-Sundberg M, "Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects", Pharmacol Ther, 116, pp.496~526 (2007)[DOI]
19. Zhu HJ, "Risperidone and paliperidone inhibit p-glycoprotein activity in vitro", Neuropsychopharmacology, 32, pp.757~764 (2007)[DOI]
20. Suzuki Y, "Impact of the ABCB1 gene polymorphism on plasma 9-hydroxyrisperidone and active moiety levels in Japanese patients with schizophrenia", J Clin Psychopharmacol, 33, pp.411~414 (2013)[DOI]
21. Perera V, "Considering CYP1A2 phenotype and genotype for optimizing the dose of olanzapine in the management of schizophrenia", Expert Opin Drug Metab Toxicol, 9, pp.1115~1137 (2013)[DOI]
22. Dervaux A, "Tobacco and schizophrenia: therapeutic aspects", Encephale, 33, pp.629~632 (2007)[DOI]
23. Olesen OV, "Olanzapine serum concentrations in psychiatric patients given standard doses: the influence of comedication", Ther Drug Monit, 21, pp.87~90 (1999)[DOI]
24. Soderberg MM, "Pharmacogenetics of olanzapine metabolism", Pharmacogenomics, 14, pp.1319~1336 (2013)[DOI]
25. Wang D, "Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability", Pharmacogenet Genomics, 15, pp.693~704 (2005)[DOI]
26. Almoguera B, "CYP2D6 poor metabolizer status might be associated with better response to risperidone treatment", Pharmacogenet Genomics, 23, pp.627~630 (2013)[DOI]
27. Moons T, "Relationship between P-glycoprotein and second-generation antipsychotics", Pharmacogenomics, 12, pp.1193~1211 (2011)[DOI]
28. de Leon J, "The pharmacokinetics of paliperidone versus risperidone", Psychosomatics, 51, pp.80~88 (2010)[DOI]
29. Yasuda K, "Interaction of cytochrome P450 3A inhibitors with P-glycoprotein", J Pharmacol Exp Ther, 303, pp.323~332 (2002)[DOI]
30. Alenius M, "Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting", J Psychiatr Res, 42, pp.884~893 (2008)[DOI]
31. Skogh E, "High correlation between serum and cerebrospinal fluid olanzapine concentrations in patients with schizophrenia or schizoaffective disorder medicating with oral olanzapine as the only antipsychotic drug", J Clin Psychopharmacol, 31, pp.4~9 (2011)[DOI]
32. Gaedigk A, "Complexities of CYP2D6 gene analysis and interpretation", Int Rev Psychiatry, 25, pp.534~553 (2013)[DOI]
33. Mas S, "Intuitive pharmacogenetics: spontaneous risperidone dosage is related to CYP2D6, CYP3A5 and ABCB1 genotypes", Pharmacogenomics J, 12, pp.255~259 (2012)[DOI]
34. Gaedigk A, "Characterization of a complex CYP2D6 genotype that caused an AmpliChip CYP450 Test no-call in the clinical setting", Clin Chem Lab Med, 52, pp.799~807 (2014)
35. Suzuki T, "Effects of genetic polymorphisms of CYP2D6, CYP3A5, and ABCB1 on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia", Ther Drug Monit, 36, pp.651~655 (2014)[DOI]
36. Sager JE, "In vitro to in vivo extrapolation of the complex drug-drug interaction of bupropion and its metabolites with CYP2D6; simultaneous reversible inhibition and CYP2D6 downregulation", Biochem Pharmacol, 123, pp.85~96 (2017)[DOI]
37. Benowitz NL, "Influence of CYP2B6 genetic variants on plasma and urine concentrations of bupropion and metabolites at steady state", Pharmacogenet Genomics, 23, pp.135~141 (2013)[DOI]
38. Zhu AZ, "Gene variants in CYP2C19 are associated with altered in vivo bupropion pharmacokinetics but not bupropion-assisted smoking cessation outcomes", Drug Metab Dispos, 42, pp.1971~1977 (2014)[DOI]
39. Pacchiarotti I, "The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders", Am J Psychiatry, 170, pp.1249~1262 (2013)[DOI]
40. Castberg I, "Effects of comedication on the serum levels of aripiprazole: evidence from a routine therapeutic drug monitoring service", Pharmacopsychiatry, 40, pp.107~110 (2007)[DOI]
41. Waade RB, "Influence of comedication on serum concentrations of aripiprazole and dehydroaripiprazole", Ther Drug Monit, 31, pp.233~238 (2009)[DOI]
42. Brandl EJ, "Genetic variation in CYP3A43 is associated with response to antipsychotic medication", J Neural Transm (Vienna), 122, pp.29~34 (2015)[DOI]
43. Kim KA, "Influence of ABCB1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of quetiapine in healthy volunteers", Pharmacogenet Genomics, 24, pp.35~42 (2014)[DOI]
44. Herbild L, "Does pharmacogenetic testing for CYP450 2D6 and 2C19 among patients with diagnoses within the schizophrenic spectrum reduce treatment costs?", Basic Clin Pharmacol Toxicol, 113, pp.266~272 (2013)[DOI]
45. Ackenheil M, "Differing response to antipsychotic therapy in schizophrenia: pharmacogenomic aspects", Dialogues Clin Neurosci, 6, pp.71~87 (2004)
46. Marazziti D, "Pharmacokinetics and pharmacodynamics of psychotropic drugs: effect of sex", CNS Spectr, 18, pp.118~127 (2013)[DOI]
47. Wilffert B, "From evidence based medicine to mechanism based medicine. Reviewing the role of pharmacogenetics", Int J Clin Pharm, 33, pp.3~9 (2011)[DOI]

관련 논문AI추천